Overview

A Sub-study to LMF237A2302 to Assess the Effect of 24 Weeks Treatment With Initial Combination of Vildagliptin Plus Metformin

Status:
Completed

Trial end date:
2008-06-06

Target enrollment:

Participant gender:

Summary

This study will evaluate the effects of treatment with vildagliptin and metformin as initial combination in newly diagnosed patients with type 2 diabetes who have very high levels of HbA1c and/or fasting plasma glucose.

Phase:

Phase 3

Details

Lead Sponsor:

Novartis

Treatments:

Metformin
Vildagliptin